pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Tagrisso · news · pharmadog
← back to Tagrisso
News mentioning Tagrisso
14
stories
18d
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
fiercebiotech
19d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
24d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
Sep 3, 26
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 17, 26
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
endpoints
Aug 13, 26
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Jul 27, 26
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
